PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications.
ClinVar Genomic variation as it relates to human health
NM_001082.5(CYP4F2):c.1297G>A (p.Val433Met)
Germline
Somatic
No data submitted for somatic clinical impact
Somatic
No data submitted for oncogenicity
Variant Details
- Identifiers
-
NM_001082.5(CYP4F2):c.1297G>A (p.Val433Met)
Variation ID: 225969 Accession: VCV000225969.11
- Type and length
-
single nucleotide variant, 1 bp
- Location
-
Cytogenetic: 19p13.12 19: 15879621 (GRCh38) [ NCBI UCSC ] 19: 15990431 (GRCh37) [ NCBI UCSC ]
- Timeline in ClinVar
-
First in ClinVar Help The date this variant first appeared in ClinVar with each type of classification.
Last submission Help The date of the most recent submission for each type of classification for this variant.
Last evaluated Help The most recent date that a submitter evaluated this variant for each type of classification.
Germline May 22, 2016 Oct 8, 2024 Mar 24, 2021 - HGVS
-
... more HGVS ... less HGVSNucleotide Protein Molecular
consequenceNM_001082.5:c.1297G>A MANE Select Help Transcripts from the Matched Annotation from the NCBI and EMBL-EBI (MANE) collaboration.
NP_001073.3:p.Val433Met missense NM_001082.4:c.1297G>A NC_000019.10:g.15879621C>T NC_000019.9:g.15990431C>T NG_007971.2:g.23454G>A P78329:p.Val433Met - Protein change
- V433M
- Other names
- -
- Canonical SPDI
- NC_000019.10:15879620:C:T
-
Functional
consequence HelpThe effect of the variant on RNA or protein function, based on experimental evidence from submitters.
- -
-
Global minor allele
frequency (GMAF) HelpThe global minor allele frequency calculated by the 1000 Genomes Project. The minor allele at this location is indicated in parentheses and may be different from the allele represented by this VCV record.
-
0.23682 (T)
-
Allele frequency
Help
The frequency of the allele represented by this VCV record.
-
1000 Genomes Project 0.23682
Exome Aggregation Consortium (ExAC) 0.27258
The Genome Aggregation Database (gnomAD), exomes 0.27314
The Genome Aggregation Database (gnomAD) 0.22058
NHLBI Exome Sequencing Project (ESP) Exome Variant Server 0.22543
Trans-Omics for Precision Medicine (TOPMed) 0.22615
1000 Genomes Project 30x 0.23173
- Links
Genes
| Gene | OMIM | ClinGen Gene Dosage Sensitivity Curation |
Variation Viewer
Help
Links to Variation Viewer, a genome browser to view variation data from NCBI databases. |
Related variants | ||
|---|---|---|---|---|---|---|
| HI score
Help
The haploinsufficiency score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
TS score
Help
The triplosensitivity score for the gene, curated by ClinGen’s Dosage Sensitivity Curation task team. |
Within gene
Help
The number of variants in ClinVar that are contained within this gene, with a link to view the list of variants. |
All
Help
The number of variants in ClinVar for this gene, including smaller variants within the gene and larger CNVs that overlap or fully contain the gene. |
|||
| CYP4F2 | - | - |
GRCh38 GRCh37 |
53 | 79 | |
Conditions - Germline
| Condition
Help
The condition for this variant-condition (RCV) record in ClinVar. |
Classification
Help
The aggregate germline classification for this variant-condition (RCV) record in ClinVar. The number of submissions that contribute to this aggregate classification is shown in parentheses. (# of submissions) |
Review status
Help
The aggregate review status for this variant-condition (RCV) record in ClinVar. This value is calculated by NCBI based on data from submitters. Read our rules for calculating the review status. |
Last evaluated
Help
The most recent date that a submitter evaluated this variant for the condition. |
Variation/condition record
Help
The RCV accession number, with most recent version number, for the variant-condition record, with a link to the RCV web page. |
|---|---|---|---|---|
| drug response (1) |
reviewed by expert panel
|
Mar 24, 2021 | RCV000211144.13 | |
| drug response (1) |
reviewed by expert panel
|
Mar 24, 2021 | RCV000211318.11 | |
| Benign (1) |
criteria provided, single submitter
|
May 12, 2023 | RCV001510827.14 | |
|
CYP4F2-related disorder
|
Likely benign (1) |
no assertion criteria provided
|
Jul 22, 2021 | RCV003977584.2 |
Submissions - Germline
| Classification
Help
The submitted germline classification for each SCV record. (Last evaluated) |
Review status
Help
Stars represent the review status, or the level of review supporting the submitted (SCV) record. This value is calculated by NCBI based on data from the submitter. Read our rules for calculating the review status. This column also includes a link to the submitter’s assertion criteria if provided, and the collection method. (Assertion criteria) |
Condition
Help
The condition for the classification, provided by the submitter for this submitted (SCV) record. This column also includes the affected status and allele origin of individuals observed with this variant. |
Submitter
Help
The submitting organization for this submitted (SCV) record. This column also includes the SCV accession and version number, the date this SCV first appeared in ClinVar, and the date that this SCV was last updated in ClinVar. |
More information
Help
This column includes more information supporting the classification, including citations, the comment on classification, and detailed evidence provided as observations of the variant by the submitter. |
|
|---|---|---|---|---|---|
|
drug response
Drug-variant association: Dosage
(Mar 24, 2021)
|
reviewed by expert panel
Method: curation
|
acenocoumarol response - Dosage
Drug used for
Atrial Fibrillation
Affected status: yes
Allele origin:
germline
|
PharmGKB
Accession: SCV000268256.4
First in ClinVar: May 22, 2016 Last updated: Dec 12, 2021
Comment:
Drug is not necessarily used to treat response condition
|
Comment:
PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in … (more)
PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications. (less)
|
|
|
drug response
(Mar 24, 2021)
|
reviewed by expert panel
Method: curation
|
warfarin response - Dosage
Affected status: yes
Allele origin:
germline
|
PharmGKB
Accession: SCV000268255.4
First in ClinVar: May 22, 2016 Last updated: Dec 12, 2021 |
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or … (more)
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance. (less)
|
|
|
Benign
(May 12, 2023)
|
criteria provided, single submitter
Method: clinical testing
|
not provided
Affected status: unknown
Allele origin:
germline
|
Labcorp Genetics (formerly Invitae), Labcorp
Accession: SCV001717968.3
First in ClinVar: Jun 15, 2021 Last updated: Feb 20, 2024 |
|
|
|
Likely benign
(Jul 22, 2021)
|
no assertion criteria provided
Method: clinical testing
|
CYP4F2-related condition
Affected status: unknown
Allele origin:
germline
|
PreventionGenetics, part of Exact Sciences
Accession: SCV004799086.2
First in ClinVar: Mar 16, 2024 Last updated: Oct 08, 2024 |
Comment:
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
|
Comment:
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
Germline Functional Evidence
| There is no functional evidence in ClinVar for this variation. If you have generated functional data for this variation, please consider submitting that data to ClinVar. |
Comment:
PharmGKB Level of Evidence 2A: Variants in Level 2A clinical annotations are found in PharmGKB’s Tier 1 Very Important Pharmacogenes (VIPs). These variants are in known pharmacogenes, implying causation of drug phenotype is more likely. These clinical annotations describe variant-drug combinations with a moderate level of evidence supporting the association. For example, the association may be found in multiple cohorts, but there may be a minority of studies that do not support the majority assertion. Level 2A clinical annotations must be supported by at least two independent publications.
Comment:
PharmGKB Level of Evidence 1A: Level 1A clinical annotations describe variant-drug combinations that have variant-specific prescribing guidance available in a current clinical guideline annotation or an FDA-approved drug label annotation. Annotations of drug labels or clinical guidelines must give prescribing guidance for specific variants (e.g. CYP2C9*3, HLA-B*57:01) or provide mapping from defined allele functions to diplotypes and phenotypes to be used as supporting evidence for a level 1A clinical annotation. Level 1A clinical annotations must also be supported by at least one publication in addition to a clinical guideline or drug label with variant-specific prescribing guidance.
Comment:
This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications).
Citations for germline classification of this variant
Help| Title | Author | Journal | Year | Link |
|---|---|---|---|---|
| VKORC1 and Novel CYP2C9 Variation Predict Warfarin Response in Alaska Native and American Indian People. | Henderson LM | Clinical and translational science | 2019 | PMID: 30821933 |
| Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals. | Danese E | Clinical pharmacology and therapeutics | 2019 | PMID: 30506689 |
| Association Between ABCB1 Polymorphism and Stable Warfarin Dose Requirements in Brazilian Patients. | Tavares LC | Frontiers in pharmacology | 2018 | PMID: 29875668 |
| Influence of genetic and non-genetic factors on acenocoumarol maintenance dose requirement in a Tunisian population. | Ajmi M | European journal of clinical pharmacology | 2018 | PMID: 29479633 |
| Bleeding predictors in patients following venous thromboembolism treated with vitamin K antagonists: Association with increased number of single nucleotide polymorphisms. | Bryk AH | Vascular pharmacology | 2018 | PMID: 29432897 |
| Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses. | Chung JE | Gene | 2018 | PMID: 29054760 |
| Warfarin Dose Model for the Prediction of Stable Maintenance Dose in Indian Patients. | Gaikwad T | Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis | 2018 | PMID: 28049362 |
| Role of CYP4F2, CYP2C19, and CYP1A2 polymorphisms on acenocoumarol pharmacogenomic algorithm accuracy improvement in the Greek population: need for sub-phenotype analysis. | Ragia G | Drug metabolism and personalized therapy | 2017 | PMID: 29252193 |
| Correlation between Rs2108622 Locus of CYP4F2 Gene Single Nucleotide Polymorphism and Warfarin Dosage in Iranian Cardiovascular Patients. | Khosropanah S | Iranian journal of pharmaceutical research : IJPR | 2017 | PMID: 29201113 |
| Effect of Genotype-Guided Warfarin Dosing on Clinical Events and Anticoagulation Control Among Patients Undergoing Hip or Knee Arthroplasty: The GIFT Randomized Clinical Trial. | Gage BF | JAMA | 2017 | PMID: 28973620 |
| Effect of Genetic Variability in the CYP4F2, CYP4F11, and CYP4F12 Genes on Liver mRNA Levels and Warfarin Response. | Zhang JE | Frontiers in pharmacology | 2017 | PMID: 28620303 |
| The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients. | Wattanachai N | European journal of clinical pharmacology | 2017 | PMID: 28550460 |
| The association between GGCX, miR-133 genetic polymorphisms and warfarin stable dosage in Han Chinese patients with mechanical heart valve replacement. | Tang XY | Journal of clinical pharmacy and therapeutics | 2017 | PMID: 28429387 |
| Influence of NR3C1 and VDR polymorphisms on stable warfarin dose in patients with mechanical cardiac valves. | Lee KE | International journal of cardiology | 2017 | PMID: 28262345 |
| Genetic polymorphisms of patients on stable warfarin maintenance therapy in a Ghanaian population. | Kudzi W | BMC research notes | 2016 | PMID: 27938396 |
| Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis. | Zhang J | Meta gene | 2016 | PMID: 27617219 |
| Influence of genetic polymorphisms in cytochrome P450 oxidoreductase on the variability in stable warfarin maintenance dose in Han Chinese. | Zeng WT | European journal of clinical pharmacology | 2016 | PMID: 27488389 |
| Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients. | Wakamiya T | Molecular diagnosis & therapy | 2016 | PMID: 27262824 |
| An expanded pharmacogenomics warfarin dosing table with utility in generalised dosing guidance. | Shahabi P | Thrombosis and haemostasis | 2016 | PMID: 27121899 |
| Impact of the CYP4F2 gene polymorphisms on the warfarin maintenance dose: A systematic review and meta-analysis. | Sun X | Biomedical reports | 2016 | PMID: 27073641 |
| Race-Specific Influence of CYP4F2 on Dose and Risk of Hemorrhage Among Warfarin Users. | Shendre A | Pharmacotherapy | 2016 | PMID: 26877068 |
| A Novel Admixture-Based Pharmacogenetic Approach to Refine Warfarin Dosing in Caribbean Hispanics. | Duconge J | PloS one | 2016 | PMID: 26745506 |
| A multi-factorial analysis of response to warfarin in a UK prospective cohort. | Bourgeois S | Genome medicine | 2016 | PMID: 26739746 |
| A Randomized Trial of Pharmacogenetic Warfarin Dosing in Naïve Patients with Non-Valvular Atrial Fibrillation. | Pengo V | PloS one | 2015 | PMID: 26710337 |
| Effects of NAD(P)H quinone oxidoreductase 1 polymorphisms on stable warfarin doses in Korean patients with mechanical cardiac valves. | Chung JE | European journal of clinical pharmacology | 2015 | PMID: 26257249 |
| Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves. | An SH | Cardiovascular therapeutics | 2015 | PMID: 26223945 |
| Race influences warfarin dose changes associated with genetic factors. | Limdi NA | Blood | 2015 | PMID: 26024874 |
| Warfarin dosage response related pharmacogenetics in Chinese population. | Li S | PloS one | 2015 | PMID: 25594941 |
| An acenocoumarol dosing algorithm exploiting clinical and genetic factors in South Indian (Dravidian) population. | Krishna Kumar D | European journal of clinical pharmacology | 2015 | PMID: 25519826 |
| A pharmacogenetics-based warfarin maintenance dosing algorithm from Northern Chinese patients. | Chen J | PloS one | 2014 | PMID: 25126975 |
| Methodological issues in the development of a pharmacogenomic algorithm for warfarin dosing: comparison of two regression approaches. | Pavani A | Pharmacogenomics | 2014 | PMID: 25084205 |
| Genetic determinants of acenocoumarol and warfarin maintenance dose requirements in Slavic population: a potential role of CYP4F2 and GGCX polymorphisms. | Wypasek E | Thrombosis research | 2014 | PMID: 25042728 |
| Effect of VKORC1, CYP2C9 and CYP4F2 genetic variants in early outcomes during acenocoumarol treatment. | Cerezo-Manchado JJ | Pharmacogenomics | 2014 | PMID: 24956252 |
| CYP4F2 1347 G > A & GGCX 12970 C > G polymorphisms: frequency in north Indians & their effect on dosing of acenocoumarol oral anticoagulant. | Rathore SS | The Indian journal of medical research | 2014 | PMID: 24927344 |
| The impact of age and CYP2C9 and VKORC1 variants on stable warfarin dose in the paediatric population. | Vear SI | British journal of haematology | 2014 | PMID: 24601977 |
| Characterizing variability in warfarin dose requirements in children using modelling and simulation. | Hamberg AK | British journal of clinical pharmacology | 2014 | PMID: 24330000 |
| Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population. | Krishna Kumar D | European journal of clinical pharmacology | 2014 | PMID: 24019055 |
| Warfarin pharmacogenetics: a controlled dose-response study in healthy subjects. | Kadian-Dodov DL | Vascular medicine (London, England) | 2013 | PMID: 24029542 |
| Warfarin anticoagulant therapy: a Southern Italy pharmacogenetics-based dosing model. | Mazzaccara C | PloS one | 2013 | PMID: 23990957 |
| Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement. | Tan SL | European journal of clinical pharmacology | 2013 | PMID: 23949431 |
| Evaluation of the effects of single-nucleotide polymorphisms in CYP3A4 and CYP4F2 on stable phenprocoumon and acenocoumarol maintenance doses. | van Schie RM | Journal of thrombosis and haemostasis : JTH | 2013 | PMID: 23510058 |
| Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population. | Özer M | Basic & clinical pharmacology & toxicology | 2013 | PMID: 23061746 |
| Effect of NQO1 and CYP4F2 genotypes on warfarin dose requirements in Hispanic-Americans and African-Americans. | Bress A | Pharmacogenomics | 2012 | PMID: 23215885 |
| Impact of the CYP4F2 p.V433M polymorphism on coumarin dose requirement: systematic review and meta-analysis. | Danese E | Clinical pharmacology and therapeutics | 2012 | PMID: 23132553 |
| Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin. | Ma C | International journal of hematology | 2012 | PMID: 23104259 |
| An acenocoumarol dosing algorithm using clinical and pharmacogenetic data in Spanish patients with thromboembolic disease. | Borobia AM | PloS one | 2012 | PMID: 22911785 |
| Effect of the VKORC1 D36Y variant on warfarin dose requirement and pharmacogenetic dose prediction. | Kurnik D | Thrombosis and haemostasis | 2012 | PMID: 22871975 |
| Retrospective evidence for clinical validity of expanded genetic model in warfarin dose optimization in a South Indian population. | Pavani A | Pharmacogenomics | 2012 | PMID: 22676192 |
| Therapeutic dosing of acenocoumarol: proposal of a population specific pharmacogenetic dosing algorithm and its validation in north Indians. | Rathore SS | PloS one | 2012 | PMID: 22629463 |
| Effects of CYP4F2 gene polymorphisms on warfarin clearance and sensitivity in Korean patients with mechanical cardiac valves. | Lee KE | Therapeutic drug monitoring | 2012 | PMID: 22549502 |
| A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation. | Wei M | Thrombosis and haemostasis | 2012 | PMID: 22534826 |
| Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients. | Liang R | Journal of thrombosis and thrombolysis | 2012 | PMID: 22528326 |
| Influence of genetics and non-genetic factors on acenocoumarol maintenance dose requirement in Moroccan patients. | Smires FZ | Journal of clinical pharmacy and therapeutics | 2012 | PMID: 22486182 |
| Influence of CYP4F2 genotype on warfarin dose requirement-a systematic review and meta-analysis. | Liang R | Thrombosis research | 2012 | PMID: 22192158 |
| CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects. | Nakamura K | Journal of clinical pharmacy and therapeutics | 2012 | PMID: 22172097 |
| Vitamin K antagonists in children with heart disease: height and VKORC1 genotype are the main determinants of the warfarin dose requirement. | Moreau C | Blood | 2012 | PMID: 22130800 |
| VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children. | Biss TT | Blood | 2012 | PMID: 22010099 |
| Translational aspects of genetic factors in the prediction of drug response variability: a case study of warfarin pharmacogenomics in a multi-ethnic cohort from Asia. | Chan SL | The pharmacogenomics journal | 2012 | PMID: 21383771 |
| Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. | Gong IY | Blood | 2011 | PMID: 21725053 |
| Proposal of pharmacogenetics-based warfarin dosing algorithm in Korean patients. | Choi JR | Journal of human genetics | 2011 | PMID: 21326313 |
| Genetic and nongenetic factors associated with warfarin dose requirements in Egyptian patients. | Shahin MH | Pharmacogenetics and genomics | 2011 | PMID: 21228733 |
| VKORC1, CYP2C9 and CYP4F2 genetic-based algorithm for warfarin dosing: an Italian retrospective study. | Zambon CF | Pharmacogenomics | 2011 | PMID: 21174619 |
| Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction. | Kringen MK | Journal of biomedicine & biotechnology | 2011 | PMID: 21127708 |
| Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients. | Singh O | Drug metabolism and pharmacokinetics | 2011 | PMID: 21084764 |
| Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. | Cha PC | Human molecular genetics | 2010 | PMID: 20833655 |
| CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement. | Cen HJ | British journal of clinical pharmacology | 2010 | PMID: 20653676 |
| Extending and evaluating a warfarin dosing algorithm that includes CYP4F2 and pooled rare variants of CYP2C9. | Sagreiya H | Pharmacogenetics and genomics | 2010 | PMID: 20442691 |
| A regression model to predict warfarin dose from clinical variables and polymorphisms in CYP2C9, CYP4F2, and VKORC1: Derivation in a sample with predominantly a history of venous thromboembolism. | Wells PS | Thrombosis research | 2010 | PMID: 20421126 |
| Impact of CYP4F2 rs2108622 on the stable warfarin dose in an admixed patient cohort. | Perini JA | Clinical pharmacology and therapeutics | 2010 | PMID: 20182420 |
| Comparative performance of gene-based warfarin dosing algorithms in a multiethnic population. | Lubitz SA | Journal of thrombosis and haemostasis : JTH | 2010 | PMID: 20128861 |
| Genetic and clinical predictors of warfarin dose requirements in African Americans. | Cavallari LH | Clinical pharmacology and therapeutics | 2010 | PMID: 20072124 |
| Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients. | Pautas E | Clinical pharmacology and therapeutics | 2010 | PMID: 19794411 |
| Effects of CYP4F2 genetic polymorphisms and haplotypes on clinical outcomes in patients initiated on warfarin therapy. | Zhang JE | Pharmacogenetics and genomics | 2009 | PMID: 19741565 |
| A genome-wide association study of acenocoumarol maintenance dosage. | Teichert M | Human molecular genetics | 2009 | PMID: 19578179 |
| A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. | Takeuchi F | PLoS genetics | 2009 | PMID: 19300499 |
| CYP4F2 is a vitamin K1 oxidase: An explanation for altered warfarin dose in carriers of the V433M variant. | McDonald MG | Molecular pharmacology | 2009 | PMID: 19297519 |
| Pharmacogenetic relevance of CYP4F2 V433M polymorphism on acenocoumarol therapy. | Pérez-Andreu V | Blood | 2009 | PMID: 19270263 |
| CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. | Borgiani P | Pharmacogenomics | 2009 | PMID: 19207028 |
| CYP4F2 genetic variant alters required warfarin dose. | Caldwell MD | Blood | 2008 | PMID: 18250228 |
| https://www.pharmgkb.org/clinicalAnnotation/1184661194 | - | - | - | - |
| https://www.pharmgkb.org/clinicalAnnotation/655385400 | - | - | - | - |
| https://www.pharmgkb.org/variant/PA166155381 | - | - | - | - |
| click to load more click to collapse | ||||
Text-mined citations for rs2108622 ...
HelpThese citations are identified by LitVar using
the rs number, so they may include citations for more than one variant
at this location. Please review the LitVar results carefully for your
variant of interest.
Record last updated Nov 25, 2024
This date represents the last time this VCV record was updated. The update may be due to an update to one of the included submitted records (SCVs), or due to an update that ClinVar made to the variant such as adding HGVS expressions or a rs number. So this date may be different from the date of the “most recent submission” reported at the top of this page.